For example, in a phase III trial of patients with stage IV non-small cell lung cancer harboring KRAS mutations, abemaciclib demonstrated improvement in progression-free survival compared with erlotinib (49), and a phase III trial of patients with recurrent stage IV squamous cell lung cancer is ongoing (NCT02154490/Lung-MAP). This evidence concerns the gene KRAS and squamous cell lung carcinoma.